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Risk assessment for metalworking fluids and cancer outcomes
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Abstract
Background—Metalworking fluids (MWF) are complex mixtures with dermal and inhalation 
exposure. Published reports reveal excess cancer risk.
Methods—Using published findings exposure response was derived for each attributable cancer 
site. Aggregate excess lifetime risk was estimated by applying a lifetable calculation.
Results—Cancer sites contributing the most attributable cases were larynx, esophagus, brain, 
female breast, and uterine cervix. With constant workplace MWF exposure of 0.1 mg/m3 over a 45 
years working life, the risk of attributable cancer was 3.7% or, excluding the less certain female 
cancers, 3.1%.
Conclusion—Substantial cancer risks occurred at 0.1 mg/m3 MWF, one fourth of the current 
NIOSH recommended exposure limit for MWF total particulate. Because ingredients in current 
MWF remain from earlier formulations, it is likely that some MWF carcinogenicity persists today. 
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Although important changes have occurred, newer agents are being continually introduced with 
little or no knowledge of chronic health risks.
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1 | INTRODUCTION
Metalworking fluids (MWF) are mixtures that vary widely across process categories 
(milling, turning, grinding, stamping, etc.), within manufacturing facilities, across 
enterprises and over time, with continually evolving constituents. The routes of exposure are 
dermal, to the bulk liquid phase from parts handling and MWF splash and mist, and by 
inhalation of dusts, mists, and vapors. The health effects of MWF exposures have been 
reviewed extensively.1–5 The International Agency for Research on Cancer (IARC) has not 
yet assessed cancer risk from exposure to metalworking fluids as a group or an exposure 
circumstance (https://monographs.iarc.fr/ENG/Publications/internrep/14-002.pdf). IARC 
considers such an assessment of medium priority for monographs during 2015–2019. 
Potential carcinogens in MWF include hydrocarbons, chlorinated paraffins, aliphatic amines, 
nitrosamines, PAHs, formaldehyde-releasing agents, diethanolamine, and many other 
specialty additives. Bioassays of two water miscible MWF found evidence for 
carcinogenicity (http://ntp.niehs.nih.gov/ntp/about_ntp/trpanel/2016/february/
tr591_peerdraft.pdf https://ntp.niehs.nih.gov/ntp/about_ntp/trpanel/2014/may/
draft_tr586_508.pdf). Respiratory disorders and performance deficits are the other major 
category of MWF health effects, observed as increased morbidity and mortality from 
nonmalignant respiratory disease, or reduced pulmonary function test results, as well as 
specific and potentially life-threatening immune-mediated disorders: adult-onset asthma and 
hypersensitivity pneumonitis (HP).6,7 MWF in the manufacturing environment provide rich 
media for microbial proliferation, sustaining a wide diversity of organisms in the bacterial, 
mold, fungal, and other orders.
During the observational studies discussed here, over 800 000 workers in the United state 
were estimated to be routinely exposed to MWF in manufacturing and maintenance 
activities (most recent NIOSH assessment).8 The exposures typically arise because MWF 
are applied as spray or liquid stream to the surfaces where metal cutting or other process 
activities occur for the purposes of lubrication, cooling, and removal of chips or other 
cutting debris.9 MWF systems exist in a range from large central systems with sumps 
containing many tens of thousands of gallons of MWF, servicing dozens of operations, to 
small self-contained systems dedicated to a single machine. Operation of MWF systems 
includes filtration steps, tramp oil separation, and continual monitoring and adjustment of 
operating parameters such as pH, biocide levels, and lubricity.10 There are four general 
classes of MWF: straight oils, soluble oils, synthetic, and semi-synthetic.11 In this risk 
assessment, all types were treated as one generic entity because: a) there is wide diversity 
within those categories and b) in many operations environmental conditions are the result of 
multiple contributing sources of MWF. There is substantial overlap in ingredients: soluble 
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oils and semi-synthetics (but not synthetics) contain straight oils as components, while 
synthetics share ingredients with soluble oils and semi-synthetics (but not straight oils).
The challenge for risk assessment is to generalize from findings in the specific worker 
populations that have been observed over several prior decades, as well as from animal 
studies usually limited to a few priority components of MWF. The patterns of association 
vary across the populations studied both in the hazard identification phase of MWF 
investigations and in subsequent studies designed specifically to estimate exposure-response. 
In this risk assessment the goal is to describe attributable aggregate cancer risks associated 
with generic MWF exposure conditions, based on human studies.
2 | METHODS
2.1 | Compilation of mortality findings
The first step identified cancer sites with statistically significant excesses in MWF-exposed 
populations based on published reviews.1,4,5 The studies contributing to this hazard 
identification step generally had insufficient retrospective exposure assessments to support a 
quantitative risk assessment; the reported associations were typically with duration in 
metalworking process classifications or with other broad generic categories. Because of the 
complex and changing compositions of MWF exposures, only gravimetric measures of the 
total mass of airborne dusts or mist exposures to any MWF are considered for risk 
assessment purposes, in some cases with restriction to the thoracic fraction.
In the second step, relative risk estimates for the specific cancer sites selected were obtained 
from published analyzes of mortality in a single cohort of workers drawn from three 
automobile manufacturing plants with diverse MWF exposures.12 For this unique cohort an 
extensive retrospective exposure assessment had been performed and a detailed work history 
compiled on over 46 000 auto workers followed from 1941 through 1994.13 Although all 
types of metalworking fluids were used in these plants soluble oils would have been the 
dominant exposure. This work was jointly funded by General Motors Corporation and the 
United Auto Workers union. The investigators selected the facilities for study without prior 
knowledge of cancer excesses there. The cancer sites included in the risk assessment and the 
publications providing exposure-response estimates are displayed in Table 1.12,14–24 All 
these studies were based on the GM-UAW cohort of Eisen et al.12 Also included in the 
cancer risk assessment were the MWF associations with cervical and breast cancer, first 
observed in this autoworker study which included a large female workforce.20 Support for a 
breast cancer association with MWF was previously reported in a large population-based 
case-control study.25 Some of the reported results duplicate earlier analyzes of this cohort; 
only the later or more detailed analyzes were used. The MWF associations for colon cancer 
and bladder cancer lacked sufficient certainty in the prior literature to be included. All risk 
estimates from the three auto plants for the cancer sites previously identified in the published 
literature as MWF-associated were included in the risk assessment regardless of value or 
statistical significance in the three UAW-GM auto plants, as is appropriate for a meta-
analysis with strong prior evidence of causal associations. In analyzes stratified on exposure 
levels, restricting to significant exposure response would bias the summary risk estimates 
upward.
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2.2 | Analysis
The contributing analyzes utilized different designs and analytical methods (see 
Supplementary Table S1). The diverse reported measures of association were transformed 
into a single, common measure of relative rate (RR) equivalent to a simple linear 
association, RR = 1 + b × cumX, from which excess relative rate (ERR) = b × cumX, and 
the exposure response (XR) = ERR/cumX = b, were derived. This step depended on the 
modeling specification scenario of which there were three (Table 2).
In the third step, combining results from the various studies, categorical, and spline analyzes 
often produced several final estimates for the same exposure-response. For each specific 
outcome, these were combined as a weighted average, the weights applied being (β/SEβ)2. 
All strata for which a mean cumulative exposure could be assigned were used. If the stratum 
mean was not reported, the geometric mean of the stratum limits was used. If the lowest 
stratum merely had an upper limit or the upper stratum had no upper limit, the stratum 
estimate was not used. Similarly, when analyzes focused on specific types of MWF, example 
straight, soluble, etc., each of these estimates was included in the outcome-specific average 
exposure response using the same weighting procedure (see Supplementary Table S1), 
recognizing that some of these MWF-specific estimates were probably confounded by 
exposures to other types of MWF. When SEβ was not reported, it was derived from the 
lower confidence limit.
Using the life-table approach as implemented in the BEIR IV report,26 which accounts for 
competing risks for the onset of a discrete outcome, together with estimates of exposure-
response for the individual cancer sites, one can estimate the excess numbers of cancer 
deaths that would occur as a result of lifetime exposures at various concentrations, that is the 
excess lifetime risk (XLTR). In this calculation, cumulative exposure is derived from the 
fixed exposure intensity and increasing age (in some analyzes with a lag). This method 
assumes irreversibility of risk and removes predicted exposure-attributable deaths from the 
population at risk with increasing age along with deaths arising from the usual causes in the 
general population. Using a national life-table constructed from Social Security data27 the 
surviving population was calculated annually through age 85 for each specified exposure 
level assuming work-related exposure starts at age 20 and ceases at age 65 for a 45 years 
exposure. The number of MWF-associated deaths in each age year was calculated by 
multiplying the surviving population (SrvPop) by the hypothetical cumulative exposure at 
the attained age and by the sum of the products of: a) the site-specific average exposure-
response estimates (b(i); Table 3), and b) the corresponding age- and site-specific national 
death rates28 (assuming equal proportions by sex and a 10% nonwhite population):
For female premenopausal breast cancer,20 the cumulative exposure metric was based on the 
prior 10 years of exposure (unlagged) as specified in the regression analysis and the 
background rate was adjusted to account for both incident (n = 46) and fatal (n = 64) cases 
up to age 51, as in the reported regression analysis.
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Thus it was assumed that the risks at different cancer sites were acting independently and 
could be summed based on the observed individual cancer site estimates. Different 
contributing studies used various lag periods to address latency in estimating exposure 
response with the majority of estimates actually calculated without a presumed lag period 
(eg, Eisen et al12). Therefore in the calculation of XLTR, lag periods of 20, 10, and 0 years 
were applied for comparison.
3 | RESULTS
The predicted attributable cancer deaths (assuming 10 years lag) totaled 0.48 per thousand 
person-year at age 60 after 40 years of work with 1.0 mg/m3-year MWF cumulative 
exposure, corresponding to 40–10 = 30 years at 0.033 mg/m3 MWF (Table 3); the 
premenopausal breast cancer contribution was calculated for age 50. The cancer sites with 
the highest estimated rates of attributable cases were for larynx with 0.18 per 1000 person-
year (at 1.0 mg/m3-year MWF) and esophagus with 0.12 per 1000 person-year followed by 
brain (0.05 per 1000) and, in women, cervix (0.05 per 1000), and breast cancer (0.04 per 
1000), (Table 3), but the estimates for the female cancer sites were based on many fewer 
person-years of observation12 and there was less prior evidence of MWF-associated risk for 
those cancer sites. Excess lifetime risk of cancer mortality attributable to MWF was 
calculated (Table 4; see Supplementary Table S2 for example of life-table calculation). With 
three assumed lag periods modest differences resulted. At a constant working life exposure 
level of 0.1 mg/m3 MWF and a 10 year lag, the XLTR was approximately 3.7 percent (37 
per 1000), and at 0.02 mg/m3 it was 0.7 percent (7 per 1000). Excluding the female cancer 
sites for which there was less supporting evidence, and with a 10 year lag, the XLTR at 0.1 
mg/m3 MWF was approximately 3.1 percent (31 per 1000), and at 0.02 mg/m3 it was 0.6 
percent (6 per 1000) (Table 4).
4 | DISCUSSION
At 0.1 mg/m3 concentrations of the MWF typically in use in the latter half of the 20th 
Century, that is at one fourth of the current NIOSH Recommended Exposure Limit (REL), 
this study suggests that substantial excess lifetime risks of fatal malignant disease (greater 
than 3 percent) remain. The primary affected cancer sites are in the upper and lower 
digestive tract. Lung cancer risks, observed to be generally small, have been hypothesized to 
reflect a protective role of endotoxin exposures generated by water-based MWF.22 Based on 
this risk assessment, cancer mortality is a candidate for the critical effect in a comprehensive 
risk assessment for MWF, as are respiratory impairment, incident asthma, and 
hypersensitivity pneumonitis, for which separate risk assessments have been conducted.
4.1 | Limitations
Although only three automotive manufacturing plants with MWF exposures were studied for 
cancer mortality, these three large plants (including transmission, gear and axle, steering 
gear, and related operations) over a period of more than 50 years produced thousands of 
specific parts on machine tools serviced by hundreds of central MWF sumps containing 
specific fluid types and ingredients considered optimal for those applications. The fluid 
formulations were those available from numerous vendors serving the entire metalworking 
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industry, not just automotive. The period of observation sampled all these systems and the 
resulting estimates of relative risk represent an average effect over this entire manufacturing 
experience. These observations should be generalizable to most large scale ferrous and 
aluminum metalworking manufacturing during that period but may not represent as well 
smaller machining operations often without central coolant systems. On the other hand, the 
plants studied had relatively little cast iron machining and grinding compared to, for 
example engine plants or bearing plants where stomach cancer excesses have been observed.
1,3,29
 No stomach cancer excess was observed in the Eisen study12 used for this risk 
assessment.
There are multiple limitations in these estimates of XLTR of cancer mortality beyond the 
uncertainties of historical MWF exposure composition. All of the non-spline reported 
statistical models using continuous exposure metrics in the estimation of exposure response 
utilized a log-linear model form which would tend to underestimate the magnitude of the 
association in the mid-range of the exposure variable, which is what was used in deriving a 
common linear exposure response metric. Although different MWF would confer different 
levels of cancer mortality risk, the estimates produced here were from the generic mix of 
MWF over the periods of observation thus diluting the contributions of specific MWF 
formulations conferring high risk but enabling the aggregation of specific cancer-site 
estimates to produce an overall summary risk of cancer death. Predicted excess relative rates 
and attributable cases for the 13 specific cancer sites in some cases were based on quite 
uncertain estimates, but the aggregate effect of these statistically independent effects would 
be more stable. Personal risk factors such as smoking were not available in most analyzes 
but all were based on internal comparisons which would tend to reduce bias from those risk 
factors. For the leading cancer sites with deaths attributable to MWF (larynx, esophagus, 
brain but not lung), smoking is a relatively small risk factor. Moreover, smoking is a risk 
factor for poor health and relatively earlier termination of employment and, thus, it would 
contribute to a healthy worker survivor bias and likely negative confounding of analyzes of 
exposure response related to cumulative exposure.
5 | CONCLUSION
Because many ingredients in current MWF remain from earlier formulations, it is reasonable 
to assume that some MWF carcinogenicity persists today. Although some important changes 
have occurred, such as elimination of acid-refined oils many years ago and reduction of 
nitrosamine-forming chemicals, newer agents are being continually introduced with little or 
no knowledge of associated chronic health risks.
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TABLE 1
Cancer sites included in risk assessment based on UAW/ General Motors study of MWF (Eisen et al 200112)
Cancer site References
Esophagus Sullivan et al 199816
Stomach Eisen et al 200112
Rectum Eisen et al 200112; Malloy et al 200721
Pancreas Bardin et al 199715
Biliary tract Bardin et al. 200519
Larynx Eisen et al 199414
Lung Mehta et al 201022
Melanoma Costello et al 201123
Breast Thompson et al 200520
Cervical Betenia et al 201224
Prostate Agalliu et al 200518
Brain Eisen et al 200112; Thurston et al 200217
Lymphopoietic Eisen et al 200112
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TABLE 2
Transformation of association measures to equivalent linear form
scen
Original model form in 
published study Linearized exposure response, b from RR = 1 + b × cumX: b = (RR–1)/cumX
1 Loglinear logistic or Poisson 
regression, on continuous 
cumulative exposure
Evaluate OR @ mean cumX (mg/m3-year) via inverse log transformation; linearize and express 
exposure response as ERR per mg/m3-year MWF:
2 Proportional hazard regression, 
spline, on continuous 
cumulative exposure
Apply reported HR @ investigator-specified cumulative exposures; linearize and express XR as ERR 
per mg/m3-year MWF:
3 Loglinear logistic or Poisson 
regression, on categorical strata 
of cumulative exposure
linearize OR @ stratum and express XR as ERR per mg/m3-year MWF:
scen, scenario; RR, relative risk; OR, odds ratio; β, reported parameter estimate; HR, hazard ratio; ERR, excess relative risk.
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TABLE 3
Estimated exposure response and attributable deaths for specific cancer site outcomes
Cancer site Exposure response (b)a Attributable proportiona Attributable deaths per 1000 P-yeara,b
Esophagus 0.596 0.373 0.117
Stomach −0.091 −0.101 −0.017
Rectum 0.135 0.119 0.015
Pancreas 0.014 0.014 0.004
Liver/bile duct 0.105 0.095 0.005
Larynx 1.994 0.666 0.179
Lung 0.008 0.008 0.022
Skin/melanoma 0.120 0.107 0.016
Breast (women)c 0.083 0.076 0.039
Cervix (women) 1.281 0.562 0.045
Prostate (men) 0.008 0.008 0.001
Brain 0.298 0.229 0.051
Lymphoid leukemia 0.005 0.005 0.000
Total - - 0.477
a
ERR per 1.0 mg/m3-year of MWF cumulative exposure; attributable proportion = ERR/(1 + ERR).
bAt age 60; with 10 year lag, 1.0 mg/m3-year cumulative exposure corresponds to 40 years at 1.0/(40–10) = 0.033 mg/m3 MWF constant 
exposure; assumes equal proportions of men and women.
c
For breast cancer at age 50, for 1.0 mg/m3-year cumulative exposure based on 10-year exposure window (corresponding to 10 years at 0.1 mg/m3 
MWF) and risk for premenopausal cancer (age < 52) (Thompson et al 2005).20
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